Eledon Pharmaceuticals (ELDN) Corporate presentation summary

Vision and strategy

• Aims to transform transplant immunosuppression with the goal of achieving "one transplant for life" by replacing calcineurin inhibitors (CNIs) with tegoprubart across all transplant types.

• Focuses on improving safety, tolerability, and long-term graft function, particularly in kidney transplantation.

Lead asset and clinical validation

• Tegoprubart is a novel anti-CD40L antibody with over 200 subjects of safety data, including more than 100 transplant patients.

• Demonstrated high levels of kidney function (eGFR) and 100% insulin independence in islet cell transplant patients.

• Safety profile suggests significant reduction in side effects compared to current standard of care.

Financial position and milestones

• Holds $88.8M in cash and equivalents as of June 30, 2026, sufficient to fund operations into Q2 2027.

• Plans to launch Phase 3 kidney and registrational islet transplant studies, new liver and xenotransplantation trials, and a subcutaneous kidney transplant study within 12 months.